Vanguard Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.4M Buy
217,958
+8,247
+4% +$884K ﹤0.01% 2467
2026
Q2
$19.4M Sell
209,711
-8,752
-4% -$542K ﹤0.01% 2464
2026
Q1
$12M Buy
+218,463
New +$13.2M ﹤0.01% 2631

Other funds holding MNPR

Vanguard Capital Management's MNPR Position: Q3 2026 in Review

Vanguard Capital Management increased its Monopar Therapeutics (MNPR) stake by 3.9% in Q3 2026, buying an estimated $884K and bringing the position to 217,958 shares worth $17.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2467.

Vanguard Capital Management first reported a position in MNPR in Q1 2026 and has held it in 3 quarters since. The position peaked at $19.4M in Q2 2026. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • Vanguard Capital Management held 217,958 shares of Monopar Therapeutics worth $17.4M as of Q3 2026.
  • Vanguard Capital Management bought 8,247 Monopar Therapeutics shares in Q3 2026, an estimated $884K.
  • Monopar Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2467 holding.
  • Vanguard Capital Management first reported a position in Monopar Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Monopar Therapeutics position peaked at $19.4M in Q2 2026.
  • 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.